Citadel Advisors - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 80 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2022. The put-call ratio across all filers is 4.85 and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$2,768,968
-11.4%
3,549,959
+5.1%
0.00%0.0%
Q2 2023$3,125,352
+151.6%
3,378,758
+196.5%
0.00%
Q1 2023$1,242,075
+231.9%
1,139,518
+344.5%
0.00%
Q4 2022$374,252
-77.7%
256,337
-83.6%
0.00%
Q3 2022$1,677,000
-37.0%
1,559,786
-0.3%
0.00%
-100.0%
Q2 2022$2,660,000
-27.9%
1,564,755
-12.6%
0.00%0.0%
Q1 2022$3,688,000
-37.8%
1,790,391
+13.2%
0.00%0.0%
Q4 2021$5,933,000
-58.4%
1,582,079
-42.7%
0.00%
-66.7%
Q3 2021$14,278,000
+1224.5%
2,761,728
+991.2%
0.00%
Q2 2021$1,078,000
-92.1%
253,102
-90.1%
0.00%
-100.0%
Q1 2021$13,563,000
+29.5%
2,554,252
+31.5%
0.00%0.0%
Q4 2020$10,471,000
-73.7%
1,942,664
-61.1%
0.00%
-72.7%
Q3 2020$39,816,000
+16.4%
4,989,446
+46.0%
0.01%
-8.3%
Q2 2020$34,197,000
+498.2%
3,416,268
+62.5%
0.01%
+300.0%
Q1 2020$5,717,000
+19613.8%
2,101,805
+10984.3%
0.00%
Q3 2019$29,000
-90.9%
18,962
-75.9%
0.00%
Q2 2019$317,000
+1.6%
78,755
+8.4%
0.00%
Q1 2019$312,000
+16.4%
72,666
+55.6%
0.00%
Q4 2018$268,000
-92.8%
46,688
-82.9%
0.00%
-100.0%
Q3 2018$3,697,000
+142.7%
272,689
+112.6%
0.00%0.0%
Q2 2018$1,523,000
+1169.2%
128,280
+1098.9%
0.00%
Q1 2018$120,000
-82.4%
10,700
-87.2%
0.00%
-100.0%
Q3 2017$683,000
+667.4%
83,423
+322.2%
0.00%
Q2 2017$89,000
-98.9%
19,759
-97.0%
0.00%
-100.0%
Q3 2015$7,844,000
+142.2%
655,279
+270.7%
0.01%
+133.3%
Q2 2015$3,239,000176,7600.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q1 2022
NameSharesValueWeighting ↓
Matrix Capital Management Company, LP 38,974,185$166,030,0001.81%
Endurant Capital Management LP 1,539,435$6,558,0001.80%
NEA Management Company, LLC 17,082,611$72,772,0000.95%
PFM Health Sciences, LP 3,627,900$15,455,0000.48%
GSA CAPITAL PARTNERS LLP 513,388$2,187,0000.25%
Baker Brothers Advisors 9,830,877$41,880,0000.18%
Avoro Capital Advisors LLC 2,024,400$8,624,0000.15%
Vigilare Wealth Management 54,250$231,0000.14%
AlphaCentric Advisors LLC 120,000$511,0000.14%
Rock Springs Capital Management LP 1,545,000$6,582,0000.13%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders